tiprankstipranks
Trending News
More News >

Cogent Biosciences price target raised to $25 from $21 at JPMorgan

JPMorgan raised the firm’s price target on Cogent Biosciences (COGT) to $25 from $21 and keeps an Overweight rating on the shares. The firm says top-line pivotal SUMMIT Part 2 data for bezuclastinib in non-advanced systemic mastocytosis is expected in July. It sees a “very favorable” reward/risk profile for Cogent shares heading into the data. JPMorgan’s “base case win scenario” is a 50% symptom benefit relative to Ayvakit in the PIONEER study.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue